Updated:
Braeburn Capital
Braeburn Capital is a specialty pharmaceutical company focused on opioid use disorder, developing long-acting injectable buprenorphine in the US.
Braeburn Capital
At Braeburn, there are opportunities to contribute to our purpose every day. We value authenticity and strive to amplify all voices. Our culture empowers everyone to be successful and unleashes our full potential.
General information
Firm type
Generalist
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Plymouth Meeting
Corporate office
450 Plymouth Rd, Suite 400, Plymouth Meeting, PA 19462
Frequently asked questions
Is Braeburn Capital an investment firm or a pharmaceutical company?
Braeburn Capital is a specialty pharmaceutical company. It focuses on developing and commercializing medication-assisted treatment for opioid use disorder, not on managing financial assets. The name 'Braeburn Capital' may suggest an investment firm, but the entity operates exclusively in the healthcare sector.
What product does Braeburn Capital commercialize?
Braeburn commercializes a long-acting injectable form of buprenorphine for treating opioid use disorder. The product is part of a category known as medication-assisted treatment. The firm promotes it through a patient-support program called Braeburn By Your Side.
Who runs investment decisions at Braeburn Capital?
Braeburn Capital does not make financial-portfolio investment decisions in the sense that a family office or asset manager would. It is an operating pharmaceutical company. Leadership decisions are corporate and clinical, not allocator-driven.
Does Braeburn Capital participate in fund commitments or direct deals?
There is no evidence that Braeburn Capital makes fund commitments or direct financial investments. Its disclosed business activities are limited to pharmaceutical development, commercialization, and community-outreach partnerships in the opioid use disorder space.
How is Braeburn Capital related to Apple Inc.'s asset-management subsidiary of the same name?
Braeburn Capital, the specialty pharmaceutical company based in Plymouth Meeting, Pennsylvania, is not related to Apple Inc.'s Nevada-based asset-management subsidiary, also called Braeburn Capital. They are separate entities sharing a name but operating in entirely different industries.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: